Last updated on October 2018

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Brief description of study

This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Clinical Study Identifier: NCT02993731

Contact Investigators or Research Sites near you

Start Over

Boston Biomedical

Istituto Ricerca e la Cura del Cancro (IRCC)
Candiolo, Italy
  Connect »

Boston Biomedical

Dermatological Hospital San Lazzaro
Torino, Italy
  Connect »